Clinical analysis of 11 cases of lymphoma complicated with paraneoplastic neurological syndrome.
10.3760/cma.j.issn.0253-2727.2022.04.008
- VernacularTitle:淋巴瘤合并神经系统副肿瘤综合征11例临床分析
- Author:
Chong WEI
1
;
Dan Qing ZHAO
1
;
Yan ZHANG
1
;
Wei WANG
1
;
Wei ZHANG
1
;
Dao Bin ZHOU
1
Author Information
1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Immunosuppression therapy;
Lymphoma;
Nervous system;
Paraneoplastic syndromes
- MeSH:
Adult;
Aged;
Antibodies, Neoplasm;
Autoantibodies;
Female;
Glucocorticoids;
Humans;
Lymphoma/diagnosis*;
Male;
Middle Aged;
Paraneoplastic Syndromes, Nervous System/complications*;
Retrospective Studies
- From:
Chinese Journal of Hematology
2022;43(4):311-315
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the clinical characteristics, treatment, and prognosis of patients with paraneoplastic neurological syndrome (PNS) associated with lymphoma. Methods: Between January 2012 and May 2021, the clinical data of 11 patients with lymphoma complicated with PNS treated at Peking Union Medical College Hospital were retrospectively reviewed. Results: Among the 11 patients (8 male and 3 female) , the median onset age was 61 (range, 33-78) years. The symptoms of PNS preceded lymphoma in 10 patients. The median time from the onset of PNS to the diagnosis of lymphoma was 4 months. Of the 11 patients, one had Hodgkin's lymphoma, 8 had B-cell non-Hodgkin's lymphoma, and 2 had peripheral T-cell lymphoma. Seven patients were evaluated for onconeural antibody, of whom 2 were positive (1 for anti-Ma2 antibody and 1 for anti-Yo antibody) . Of the 11 patients, the PNS symptoms of 3 patients were located in the central nervous system, 4 were located in the peripheral nervous system, and 3 were located in the muscle. Eight of the 11 patients were treated with glucocorticoid-based immunosuppressive therapy before the diagnosis of lymphoma. Patients with central nervous system involvement and dermatomyositis responded well to glucocorticoid, whereas patients with peripheral neuropathy did not significantly benefit. All 11 patients were treated with chemotherapy after the diagnosis of lymphoma. The efficacy of chemotherapy was assessed in 9 patients, 7 cases achieved complete remission, 1 case was evaluated as stable disease, and 1 case was evaluated as disease progression. The PNS symptoms of the patients who achieved complete response were almost completely recovered. The median follow-up time was 42 (range, 4-95) months. At the end of the follow-up period, 6 of the 11 patients survived, 3 were lost to follow-up, and 2 died. The median overall survival of the whole group was not reached. Conclusions: PNS can involve various parts of the nervous system and can be associated with different types of lymphoma. Through early diagnosis and treatment, the PNS symptoms could improve in most patients who achieve complete remission of lymphoma.
